tiprankstipranks
pc:nuevo

Nuevocor

Singapore, SG
https://www.nuevocor.com/
Nuevocor is a Singapore-headquartered biotechnology company focused on developing treatments for cardiomyopathies caused by aberrant mechanobiology. The company is advancing its lead candidate, NVC-001, targeting LMNA-related dilated cardiomyopathy, through Phase 1/2 clinical trials to establish clinical proof-of-concept.

Leadership & Board

Current Number of Employees29
Current LinkedIn Followers2,688

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$45M
Total Amount Raised$45M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$45M
Latest Funding Amount$45M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation
Post-Money Valuation

Employee Trend

Nuevocor had 29 employees as of April 6, 2026. The number of employees decreased by 1 (3.33%) week-over-week.
29Latest Employee Count
1(-3.33%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.

Social Trend

Nuevocor had 2,688 followers as of April 6, 2026. The number of followers increased by 8 (0.30%) week-over-week.
2,688Latest Followers Count
8(0.30%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
May 06, 2025
Series B
$45.00M

Investors

Investor Name
Funding Round

Related News and Analysis